Research programme: human papillomavirus vaccine - Pathovax

Drug Profile

Research programme: human papillomavirus vaccine - Pathovax

Alternative Names: RGVax

Latest Information Update: 03 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator PathoVax
  • Class Papillomavirus vaccines; Virus-like particle vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Human papillomavirus infections

Most Recent Events

  • 03 Apr 2018 Preclinical trials in Human papillomavirus infections (Prevention) in USA (Parenteral) (Pathovax pipeline, April 2018)
  • 02 Jan 2018 Pathovax receives phase I SBIR grants from National Institute of Allergy and Infectious Diseases and National Science Foundation for human papillomavirus vaccine development for Human papillomavirus infections (Pathovax website, April 2018)
  • 21 Sep 2017 Pathovax receives phase I STTR grant from National Institutes of Health for human papillomavirus vaccine development for Human papillomavirus infections (Pathovax website, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top